Journal article
Small molecules targeting Mcl-1: The search for a silver bullet in cancer therapy
D Nhu, G Lessene, DCS Huang, CJ Burns
Medchemcomm | ROYAL SOC CHEMISTRY | Published : 2016
DOI: 10.1039/c5md00582e
Abstract
Mcl-1 (myeloid-cell-leukemia-sequence-1) is a pro-survival member of the Bcl-2 family of proteins. Mcl-1 has been shown to be critical to the survival of a variety of cancer cells and to mediate resistance to conventional and targeted chemotherapeutics. Whilst potent and selective small molecule inhibitors of Bcl-2 and Bcl-XL have been developed, the discovery of selective inhibitors of Mcl-1 has proven more problematic and only very recently have potent and selective inhibitors been described. In this review we outline key features of Mcl-1 biology, and chemical approaches and outcomes of inhibiting this important survival protein for the treatment of cancers.
Grants
Awarded by Australian National Health and Medical Research Council
Awarded by Leukemia & Lymphoma Society (Specialized Center of Research)
Funding Acknowledgements
This work is supported by scholarships, fellowships and grants from the Australian National Health and Medical Research Council (GNT1057742; Research Fellowship to DCSH), Victorian State Government Operational Infrastructure Support (OIS) Grant, Australian Cancer Research Foundation, The Leukemia & Lymphoma Society (Specialized Center of Research 7001-13), Cancer Therapeutics CRC (DN) and Dyson Bequest funding (Dunn Fellowship to CJB). We thank Dr David Segal and Dr Lisa Lindqvist for providing useful comments in the preparation of this manuscript.